Dr. Hamilton on the KATHERINE Trial in HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Monday, Dec 02, 2019



Erika P. Hamilton, MD, director, Breast Cancer Program, Sarah Cannon Research Institute, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.
 
The KATHERINE trial accrued patients who did not have a pathologic complete response at surgery after completing neoadjuvant chemotherapy and HER2-targeted therapy. Patients were randomized to receive 14 cycles of adjuvant trastuzumab (Herceptin) or ado-trastuzumab emtansine (T-DM1; Kadcyla).
 
Results showed a 50% reduction in the risk of invasive disease recurrence or death with T-DM1 versus trastuzumab (HR, 0.50; 95% CI, 0.39-0.64; P <.001). 
 
Despite some toxicity concerns with T-DM1, the agent displays a greater invasive disease-free survival benefit compared with adjuvant neratinib (Nerlynx) or pertuzumab (Perjeta), says Hamilton.
 
These data suggest that investigators may be able to identify high-risk patients based on their response to neoadjuvant chemotherapy rather than tumor size or nodal status at diagnosis, concludes Hamilton. 
 
SELECTED
LANGUAGE


Erika P. Hamilton, MD, director, Breast Cancer Program, Sarah Cannon Research Institute, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.
 
The KATHERINE trial accrued patients who did not have a pathologic complete response at surgery after completing neoadjuvant chemotherapy and HER2-targeted therapy. Patients were randomized to receive 14 cycles of adjuvant trastuzumab (Herceptin) or ado-trastuzumab emtansine (T-DM1; Kadcyla).
 
Results showed a 50% reduction in the risk of invasive disease recurrence or death with T-DM1 versus trastuzumab (HR, 0.50; 95% CI, 0.39-0.64; P <.001). 
 
Despite some toxicity concerns with T-DM1, the agent displays a greater invasive disease-free survival benefit compared with adjuvant neratinib (Nerlynx) or pertuzumab (Perjeta), says Hamilton.
 
These data suggest that investigators may be able to identify high-risk patients based on their response to neoadjuvant chemotherapy rather than tumor size or nodal status at diagnosis, concludes Hamilton. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x